睿昂基因(688217) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 173,999,859.70, a decrease of 28.19% compared to the previous year[2] - Operating profit was -RMB 53,503,630.90, with a loss increase of RMB 25,081,856.18 year-on-year[2] - Net profit attributable to shareholders was -RMB 49,883,617.84, reflecting an increase in loss of RMB 34,119,502.19 compared to the previous year[2] - Basic earnings per share were -RMB 0.90, a decline of RMB 0.62 from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 889,656,452.10, down 9.74% from the beginning of the period[2] - Equity attributable to shareholders decreased by 6.52% to RMB 849,990,809.25 compared to the beginning of the period[2] Market Conditions - The decline in revenue was attributed to intensified competition in the in vitro diagnostics industry and specific events affecting the company[5] - The company recognized impairment losses on its molecular diagnostic reagent R&D center and subsidiaries due to adverse market conditions[6] - The company anticipates limited taxable income in the future, leading to the write-off of previously recognized deferred tax assets[6] Audit and Reporting - The financial data presented is preliminary and subject to final audit in the 2025 annual report[7]